CML-CP On Treatment
(4620 Patient-Months), %
CML-CP Post-Discontinuation
(1644 Patient-Months), %
CML-AP/BC
(25 593 Patient-Months), %
Post-HSCTa
(300 Patient-Months), %
TKI alone
Nilotinib 40.1 9.3 9.4 22.0
Imatinib 27.8 32.7 33.5 28.6
Dasatinib 20.8 26.5 9.9 18.8
Bosutinib 8.2 23.3 0.9 8.6
Ponatinib 3.1 7.0 0.6 19.1
Omacetaxine 0.0 1.1 0.0 0.0
TKI and AML/ALL-like chemotherapy 1.2 3.0
AML/ALL-like chemotherapy alone 1.2
Interferon alone 0.0
Hydroxyurea alone 0.8
No treatment 42.5